Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03378466 · ClinicalTrials.gov registry record · Phase 2
Heparin Anticoagulation in Septic Shock
A Phase 2 study, sponsored by University of Manitoba.
- Terminated
- Registry status
- Phase 2
- Development phase
- 178
- Enrollment target
NCT03378466 is a Phase 2 study that was terminated before completion, run by University of Manitoba. The registered enrollment target is 178 participants.
The verdict
NCT03378466, a Phase 2 study, was terminated before completion, sponsored by University of Manitoba.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 178 participants
- Enrollment target
Study Summary
This study is a pragmatic open-label international randomized trial comparing therapeutic dose intravenous unfractionated heparin (UFH) to standard care venous thromboprophylaxis in patients diagnosed with septic shock.
Interventions
- DRUG Unfractionated heparin
- OTHER Venous thromboprophylaxis (VTE)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2018-03-12 |
| Est. Completion | 2021-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03378466
The ClinicalTrials.gov registry entry for NCT03378466 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 178 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Manitoba, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Unfractionated heparin is the first listed.
NCT03378466 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03378466 about?
NCT03378466 is a clinical study titled "Heparin Anticoagulation in Septic Shock". This study is a pragmatic open-label international randomized trial comparing therapeutic dose intravenous unfractionated heparin (UFH) to standard care venous thromboprophylaxis in patients diagnosed with septic shock.
What is the current status of trial NCT03378466?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 178 participants. The study started on 2018-03-12. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT03378466?
The interventions under investigation include: Unfractionated heparin (DRUG), Venous thromboprophylaxis (VTE) (OTHER).
Who is sponsoring clinical trial NCT03378466?
This trial is sponsored by University of Manitoba, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.